Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora’s failed trials and layoffs signal deep trouble, not a turnaround opportunity.

What the company is saying

Neumora Therapeutics is attempting to frame its recent setbacks as part of a process rather than a terminal failure. The company’s core narrative, as presented, is that despite the failure of both Phase 3 KOASTAL-2 and KOASTAL-3 trials for navacaprant in major depressive disorder, management remains 'pleased with the significant progress' made in the program. This language is carefully chosen to project resilience and ongoing value, even as the underlying facts are negative. The announcement emphasizes the trial failures and the immediate ~35% workforce reduction, but management’s public statements, particularly from COO Aurora, focus on next steps only 'following a successful readout,' which is now moot given the failed outcomes. There is a notable omission of any discussion regarding the workforce reduction during the Q4 2025 earnings call, suggesting a desire to downplay the operational impact and avoid alarming investors further. President Pinto’s earlier communication about increasing the patient population by 25% in the studies is referenced, but this is now irrelevant given the negative results. The tone from management is incongruently upbeat in the face of clear setbacks, likely an attempt to maintain investor confidence or at least prevent panic. Notable individuals such as COO Aurora and President Pinto are mentioned, but there is no evidence of outside institutional support or high-profile new investors stepping in. Overall, the narrative fits a defensive investor relations strategy: acknowledge the facts, but try to soften the blow and avoid triggering further selloff or litigation risk. There is no evidence of a shift toward transparency or a new strategic direction; if anything, the messaging is more evasive than in a typical post-failure disclosure.

What the data suggests

The disclosed numbers paint a stark and unambiguous picture of deterioration. The most significant data points are the failure of both Phase 3 KOASTAL-2 and KOASTAL-3 trials and the immediate ~35% workforce reduction, both of which are clear indicators of a major setback. The stock’s nearly 50% drop is a direct market response to these failures, reflecting a dramatic loss of investor confidence and perceived future value. There is no evidence that prior targets or guidance were met; in fact, the increase in patient population by 25% in the studies, as discussed by President Pinto, did not translate into positive outcomes. The financial disclosures are notably incomplete: there is no mention of revenue, cash position, burn rate, or any other operational metrics that would allow an investor to assess the company’s ongoing viability. This lack of transparency is itself a red flag, as it prevents any meaningful comparison to prior periods or industry benchmarks. An independent analyst, looking solely at the numbers, would conclude that Neumora is in a crisis: its lead asset has failed, it is cutting a third of its workforce, and its market value has been halved. The absence of any positive financial or operational data further underscores the severity of the situation. The only numbers provided are event-driven and negative, with no evidence of a plan for recovery or new value creation.

Analysis

The announcement is dominated by negative realised events: both Phase 3 trials failed, the stock fell nearly 50%, and an immediate ~35% workforce reduction was announced. There is only one minor forward-looking claim ('plans on next steps only following a successful readout'), which is conditional and not promotional. The language from management ('pleased with the significant progress') is incongruent with the negative outcomes, but this is not paired with any exaggerated claims of future success or recovery. No large capital outlay or aspirational projections are present. The legal investigation is factual and not hyped. Overall, the narrative is not inflated relative to the disclosed evidence; if anything, the tone is muted given the severity of the setbacks.

Risk flags

• ●Lead asset failure: The failure of both Phase 3 KOASTAL-2 and KOASTAL-3 trials eliminates the company’s primary value driver. This is a catastrophic event for a biotech at this stage, as it leaves the pipeline and future revenue prospects in question.
• ●Massive workforce reduction: The immediate ~35% cut in staff signals severe cost pressures and likely operational disruption. Such a large reduction often leads to loss of institutional knowledge, morale issues, and impaired ability to execute on any remaining programs.
• ●Stock collapse: A nearly 50% drop in share price reflects a market consensus that the company’s prospects have fundamentally deteriorated. This also increases the risk of delisting, hostile takeover, or further capital constraints.
• ●Opaque financial disclosure: The announcement omits key financial metrics such as cash position, burn rate, and runway. This lack of transparency makes it impossible for investors to assess the company’s ability to survive or pivot.
• ●Litigation risk: The initiation of a securities investigation by Levi & Korsinsky, LLP into potentially false or misleading statements about financial condition and clinical program status introduces the risk of costly legal proceedings, settlements, or regulatory penalties.
• ●Forward-looking claims are now moot: The only forward-looking statement—plans for next steps after a successful readout—is no longer relevant, as the readout was negative. This leaves investors with no credible path to future value.
• ●No evidence of institutional support: There is no mention of new investment, partnerships, or support from major industry players. The absence of such backing increases the risk that the company will be unable to raise additional capital or attract strategic interest.
• ●Pattern of evasive communication: Management’s failure to mention the workforce reduction during the earnings call, despite its materiality, suggests a tendency to downplay negative developments. This pattern increases the risk of further unpleasant surprises for investors.

Bottom line

For investors, this announcement is a clear signal to reassess any bullish thesis on Neumora Therapeutics. The failure of both pivotal Phase 3 trials for navacaprant removes the company’s main value proposition and leaves its future highly uncertain. The immediate ~35% workforce reduction is a drastic measure that underscores the severity of the setback and likely impairs the company’s ability to execute on any remaining pipeline assets. The nearly 50% collapse in share price is a rational market response to these events, and there is no evidence of a credible recovery plan or new strategic direction. The initiation of a securities litigation investigation by a top-ranked firm further increases the risk profile, as it could lead to costly legal outcomes and further erode shareholder value. Management’s communications are evasive and fail to provide the transparency or forward guidance that investors need to make informed decisions. To change this assessment, the company would need to disclose detailed financials (cash runway, burn rate), a concrete plan for pipeline reprioritization, and clear milestones for any new programs. In the next reporting period, investors should watch for updates on cash position, any new clinical or business development initiatives, and the status of the legal investigation. At present, the information provided is a strong negative signal—this is not a buying opportunity, but rather a situation to monitor for further deterioration or, at best, signs of stabilization. The single most important takeaway is that Neumora’s investment case has fundamentally changed for the worse, and absent new, credible disclosures, the risk of further downside remains high.

Announcement summary

(NASDAQ: NMRA) Neumora Therapeutics reported that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder, resulting in the stock falling nearly 50%. The company announced an immediate ~35% workforce reduction following the trial failures. During its Q4 2025 earnings call on March 30, 2026, COO Aurora discussed plans on next steps only following a successful readout and made no mention of the workforce reduction. On January 5, 2026, Neumora's President Pinto discussed the company's decision to increase the size of the patient population by 25% in the KOASTAL-2 and KOASTAL-3 studies. Levi & Korsinsky, LLP, a Top 50 securities litigation firm (ISS, seven consecutive years), is investigating whether Neumora Therapeutics made materially false or misleading statements regarding its financial condition, asset values, and the status of its navacaprant clinical program. Over 70 professionals at Levi & Korsinsky, LLP have recovered hundreds of millions. The investigation covers investors who purchased NMRA stock or securities and suffered financial losses.

Disagree with this article?